- Home
- CIFR vs TARS Comparison
CIFR vs TARS Comparison
Compare CIFR & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIFR
- TARS
- Stock Information
- Founded
- CIFR 2021
- TARS 2016
- Country
- CIFR United States
- TARS United States
- Employees
- CIFR N/A
- TARS N/A
- Industry
- CIFR Investment Bankers/Brokers/Service
- TARS Medicinal Chemicals and Botanical Products
- Sector
- CIFR Finance
- TARS Health Care
- Exchange
- CIFR Nasdaq
- TARS Nasdaq
- Market Cap
- CIFR 2.1B
- TARS 1.7B
- IPO Year
- CIFR N/A
- TARS 2020
- Fundamental
- Price
- CIFR $10.85
- TARS $49.36
- Analyst Decision
- CIFR Strong Buy
- TARS Strong Buy
- Analyst Count
- CIFR 10
- TARS 7
- Target Price
- CIFR $7.63
- TARS $67.14
- AVG Volume (30 Days)
- CIFR 36.0M
- TARS 652.0K
- Earning Date
- CIFR 10-30-2025
- TARS 11-12-2025
- Dividend Yield
- CIFR N/A
- TARS N/A
- EPS Growth
- CIFR N/A
- TARS N/A
- EPS
- CIFR N/A
- TARS N/A
- Revenue
- CIFR $158,849,000.00
- TARS $295,521,000.00
- Revenue This Year
- CIFR $86.84
- TARS $33,170.29
- Revenue Next Year
- CIFR $70.70
- TARS N/A
- P/E Ratio
- CIFR N/A
- TARS N/A
- Revenue Growth
- CIFR 0.11
- TARS 254.45
- 52 Week Low
- CIFR $1.86
- TARS $30.23
- 52 Week High
- CIFR $10.92
- TARS $59.76
- Technical
- Relative Strength Index (RSI)
- CIFR 78.50
- TARS 36.86
- Support Level
- CIFR $7.08
- TARS $55.45
- Resistance Level
- CIFR $8.78
- TARS $59.76
- Average True Range (ATR)
- CIFR 0.91
- TARS 2.01
- MACD
- CIFR 0.35
- TARS -1.34
- Stochastic Oscillator
- CIFR 98.47
- TARS 8.77
About CIFR Cipher Mining Inc.
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.